I 
119TH CONGRESS 
1ST SESSION H. R. 2767 
To advance research to achieve medical breakthroughs in brain tumor treat-
ment and improve awareness and adequacy of specialized cancer and 
brain tumor care. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 9, 2025 
Mr. FITZPATRICK (for himself, Mrs. TRAHAN, Mr. JOYCE of Pennsylvania, 
and Ms. SCHRIER) introduced the following bill; which was referred to the 
Committee on Energy and Commerce 
A BILL 
To advance research to achieve medical breakthroughs in 
brain tumor treatment and improve awareness and ade-
quacy of specialized cancer and brain tumor care. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
(a) SHORT TITLE.—This Act may be cited as the 
‘‘Bolstering Research And Innovation Now Act’’ or the 
‘‘BRAIN Act’’. 
(b) TABLE OF CONTENTS.—The table of contents of 
this Act is as follows: 
Sec. 1. Short title; table of contents. 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00001
Fmt 6652
Sfmt 6211
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
Sec. 2. Findings; purposes. 
Sec. 3. Fostering transparency of biospecimen collections for brain cancer re-
search. 
Sec. 4. Glioblastoma Therapeutics Network; brain tumor related cellular 
immunotherapy (including CAR–T) team science award. 
Sec. 5. Cancer clinical trials and biomarker testing national public awareness 
campaign. 
Sec. 6. Pilot programs to develop, study, or evaluate approaches to monitoring 
and caring for brain tumor survivors. 
Sec. 7. FDA guidance to ensure brain tumor patient access to clinical trials. 
SEC. 2. FINDINGS; PURPOSES. 
(a) FINDINGS.—Congress finds as follows: 
(1) According to the National Brain Tumor So-
ciety based on data analyzed in 2024, more than 
1,000,000 people in the United States are living 
with a brain tumor and approximately 94,000 were 
estimated to be diagnosed with a primary brain 
tumor in 2023. 
(2) Brain tumors do not discriminate and can 
affect people of all races, genders, and ages. Trag-
ically, pediatric brain tumors are the leading cause 
of cancer-related death among children and young 
adults ages 19 and younger. 
(3) For malignant brain tumors, incidence and 
survival rates have remained stagnant for 45 years, 
with an average 5-year relative survival rate of 35.7 
percent and only 6.9 percent for glioblastoma, the 
most common primary malignant brain tumor. 
(4) Most primary brain tumors are non-malig-
nant, but many still require surgery and radiation. 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
The results of available treatment options can vary 
from a successful return to normal life to possible 
disability or a life-threatening condition. 
(5) Despite the statistics described in para-
graphs (1) through (4), there have been very few 
treatments ever approved by the Food and Drug Ad-
ministration to treat brain tumors, thereby resulting 
in little change in mortality rates for individuals 
with brain tumors. 
(6) As of the date of enactment of this Act, 
there is no prevention and no early detection pro-
tocol for brain tumors. 
(7) All people in the United States have a stake 
in reducing and eliminating brain tumors. 
(8) Patients living with a brain tumor and their 
families want cures. Short of cures, they want safe 
and effective ways to increase survival rates for such 
patients and improve the quality of life for such pa-
tients. 
(b) PURPOSES.—The purposes of this Act are to— 
(1) strengthen research and treatment develop-
ment regarding brain tumors; and 
(2) improve the adequacy and awareness of, 
and access to, specialized brain tumor, and rare and 
recalcitrant cancer, health care. 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
SEC. 3. FOSTERING TRANSPARENCY OF BIOSPECIMEN COL-
LECTIONS FOR BRAIN CANCER RESEARCH. 
Part A of title IV of the Public Health Service Act 
(42 U.S.C. 281 et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 404P. REPORTING OF BRAIN TUMOR BIOSPECIMEN 
COLLECTIONS. 
‘‘(a) DEFINITION OF COVERED BIOSPECIMEN COL-
LECTION.— 
‘‘(1) IN GENERAL.—In this section, the term 
‘covered biospecimen collection’ means a biospecimen 
that was collected or acquired in whole or in part 
through funding from the National Institutes of 
Health. 
‘‘(2) BIOSPECIMEN.—For purposes of para-
graph (1), the term ‘biospecimen’ means a brain 
tumor tissue, cerebral spinal fluid, or other specimen 
type listed by the Specimen Resource Locator of the 
National Cancer Institute (or a successor database). 
‘‘(b) 
ESTABLISHMENT.—The 
Secretary, 
acting 
through the Director of NIH, may establish and maintain 
a searchable website, or multiple websites, which may in-
clude websites existing on the day before the date of enact-
ment of this section, for the purpose of making accessible 
to the public— 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
‘‘(1) information on the existence and location 
of covered biospecimen collections; 
‘‘(2) a description of such collections; and 
‘‘(3) contact information with respect to such 
collections. 
‘‘(c) REPORTING REQUIREMENTS.— 
‘‘(1) EXISTING COLLECTIONS.—Any individual 
or entity that as of the date of enactment of this 
section maintains a covered biospecimen collection 
shall, not later than 180 days after such date of en-
actment, submit a report to the Director of NIH 
containing information with respect to such covered 
biospecimen collection as the Director of NIH may 
specify, including at a minimum the information the 
National Cancer Institute requires for the Specimen 
Resource Locator (or a successor database). 
‘‘(2) NEW
COLLECTIONS.—Any individual or 
entity that collects or acquires a covered biospecimen 
collection on or after the date of enactment of this 
section shall, not later than 60 days after the date 
of such collection or acquisition, submit a report to 
the Director of NIH containing the information re-
quired under paragraph (1). 
‘‘(d) OVERSIGHT.—The Secretary, acting through the 
Director of NIH, shall establish and carry out an oversight 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
mechanism, which shall include withholding funding to in-
dividuals or entities that have committed a repeated or 
egregious violation of the requirements under subsection 
(c).’’. 
SEC. 4. GLIOBLASTOMA THERAPEUTICS NETWORK; BRAIN 
TUMOR 
RELATED 
CELLULAR 
IMMUNOTHERAPY (INCLUDING CAR–T) TEAM 
SCIENCE AWARD. 
(a) IN GENERAL.—Subpart 1 of part C of title IV 
of the Public Health Service Act (42 U.S.C. 285 et seq.) 
is amended by adding at the end the following: 
‘‘SEC. 417H. GLIOBLASTOMA THERAPEUTICS NETWORK. 
‘‘(a) IN GENERAL.—The Director of the Institute 
shall carry out a research program, known as the ‘Glio-
blastoma Therapeutics Network’, by awarding, on a com-
petitive basis, cooperative agreements, or other awards, 
through the U19 funding mechanism of the National In-
stitutes of Health for collaboration of institutions to im-
prove the treatment of glioblastoma by evaluating thera-
peutic agents from pre-clinical development studies 
through completion of early-phase clinical trials in hu-
mans. 
‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated $50,000,000 for each of 
fiscal years 2026 through 2030, to remain available until 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB
expended, to the Director of the Institute to carry out this 
section. 
‘‘SEC. 
417I. 
BRAIN 
TUMOR 
RELATED 
CELLULAR 
IMMUNOTHERAPY (INCLUDING CAR–T) TEAM 
SCIENCE AWARD. 
‘‘(a) IN GENERAL.—In order to take advantage of 
the significant advancement in the development of brain 
tumor related cellular immunotherapy, including chimeric 
antigen receptor–T (in this section referred to as ‘CAR– 
T’), including many such approaches previously funded by 
the National Institutes of Health, the Director of the In-
stitute shall make awards, on a competitive basis, through 
a U series funding mechanism, to support the development 
of a multi-institutional team science approach to using 
brain tumor related cancer cellular immunotherapy, in-
cluding CAR–T treatment, for adult and pediatric brain 
tumors. 
‘‘(b) USE OF FUNDS.—Funds received through an 
award under this section shall be used— 
‘‘(1) to support collaborative, multi-institutional 
research activities, including pre-clinical and inves-
tigational new drug studies; and 
‘‘(2) for the purpose of supporting clinical trials 
to evaluate brain tumor related cancer cellular 
immunotherapy, including CAR–T. 
VerDate Sep 11 2014 
08:07 Apr 22, 2025
Jkt 000000
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2767.IH
H2767
mprince on LAP1J3WLY3PROD with $$_JOB